{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:39:15Z","timestamp":1792463955231,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004720.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000}}],"reference-count":343,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004720.pub4","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:16:41Z","timestamp":1778804201000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prostate-specific antigen (PSA) test for prostate cancer screening"],"prefix":"10.1002","volume":"2026","author":[{"given":"Juan VA","family":"Franco","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK \u2013 D\u00fcsseldorf Subunit, Institute of General Practice; Heinrich Heine University D\u00fcsseldorf; D\u00fcsseldorf Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hung","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Urology; Yonsei University Wonju College of Medicine; Wonju Korea, South"},{"name":"Center of Evidence-Based Medicine, Institute of Convergence Science; Yonsei University; Seoul Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Vaimberg","sequence":"additional","affiliation":[{"name":"School of Medicine; Universidad del Hospital Italiano de Buenos Aires; Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Ilic","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cleves","sequence":"additional","affiliation":[{"name":"Velindre NHS Trust; Cardiff University Library Services; Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-2553","authenticated-orcid":false,"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"},{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1046\/j.1464-410X.2003.04232.x","article-title":"A systematic review and meta-analysis of familial prostate cancer risk","volume":"91","author":"Johns","year":"2003","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0004|cit4","unstructured":"Cornford P Tilki D Van den Bergh RC Eberli D De Meerleer G De Santis M EAU - EANM - ESTRO ESUR - ISUP - SIOG Guidelines on Prostate Cancer https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1056\/NEJMoa075819","article-title":"Cumulative association of five genetic variants with prostate cancer","volume":"358","author":"Zheng","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004720.pub4-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"45","key":"10.1002\/14651858.CD004720.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jncimonographs\/lgs035","article-title":"Trends in prostate cancer in the United States","volume":"2012","author":"Brawley","year":"2012","journal-title":"Journal of the National Cancer Institute. Monographs"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1016\/j.ejca.2009.05.021","article-title":"Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study","volume":"45","author":"Collin","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.juro.2016.08.092","article-title":"Prognostic significance of digital rectal examination and prostate specific antigen in the prostate, lung, colorectal and ovarian (PLCO) cancer screening arm","volume":"197","author":"Halpern","year":"2017","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0014|cit14","first-page":"CD012663","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004720.pub4-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD004720.pub4-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.juro.2009.10.046","article-title":"An update of the Gleason grading system","volume":"183","author":"Epstein","year":"2010","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"American Journal of Surgical Pathology"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part III: principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"Journal of Urology"},{"issue":"16","key":"10.1002\/14651858.CD004720.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality \u2013 the future of PSA screening","volume":"382","author":"Welch","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/jamasurg.2022.0669","article-title":"Cancer screening \u2013 the good, the bad, and the ugly","volume":"157","author":"Welch","year":"2022","journal-title":"JAMA Surgery"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jamainternmed.2023.3781","article-title":"Testing whether cancer screening saves lives: implications for randomized clinical trials of multicancer screening","volume":"183","author":"Welch","year":"2023","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/clinchem\/hvad127","article-title":"Cancer screening, incidental detection, and overdiagnosis","volume":"70","author":"Welch","year":"2024","journal-title":"Clinical Chemistry"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M17-2012","article-title":"Prostate cancer screening: time to question how to optimize the ratio of benefits and harms","volume":"167","author":"Vickers","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"124\u20137","DOI":"10.3109\/13685538.2015.1131260","article-title":"Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia","volume":"19","author":"Coban","year":"2016","journal-title":"Aging Male"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"1072\u20136","DOI":"10.1016\/j.urology.2009.11.056","article-title":"Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes","volume":"76","author":"Carvalhal","year":"2010","journal-title":"Urology"},{"issue":"22","key":"10.1002\/14651858.CD004720.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"j4200","DOI":"10.1136\/bmj.j4200","article-title":"Future of screening for prostate cancer","volume":"358","author":"Dahm","year":"2017","journal-title":"BMJ"},{"issue":"31","key":"10.1002\/14651858.CD004720.pub4-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720.pub3","article-title":"Screening for prostate cancer","author":"Ilic","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/pros.20017","article-title":"Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial","volume":"59","author":"Labrie","year":"2004","journal-title":"Prostate"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"d1539","DOI":"10.1136\/bmj.d1539","article-title":"Randomised prostate cancer screening trial: 20-year follow-up","volume":"342","author":"Sandblom","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"doi: 10.1016\/j.","DOI":"10.1016\/j.juro.2018.01.080","article-title":"Long-term outcome of a single intervention population based prostate cancer screening study","volume":"200","author":"Lundgren","year":"2018","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/bmj.328.7439.535","article-title":"What's the e for EBM?","volume":"328","author":"Strauss","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720.pub2","article-title":"Screening for prostate cancer","author":"Ilic","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"c4543","DOI":"10.1136\/bmj.c4543","article-title":"Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials","volume":"341","author":"Djulbegovic","year":"2010","journal-title":"BMJ"},{"issue":"17","key":"10.1002\/14651858.CD004720.pub4-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.2018.3712","article-title":"Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Fenton","year":"2018","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0045|cit45","first-page":"297","article-title":"Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"68","author":"Smith","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/ju.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0047|cit47","unstructured":"National Institute for Health and Care Excellence (NICE) NG131: Prostate cancer: diagnosis and management; updated 2021 https:\/\/www.nice.org.uk\/guidance\/ng131"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0050|cit50","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews Cochrane: London; Version August 2023"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720","article-title":"Screening for prostatic cancer","author":"Ilic","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","volume":"49","author":"Mariotto","year":"2014","journal-title":"Journal of the National Cancer Institute Monographs"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331(17)","author":"Martin","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD004720.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1038\/bjc.2014.242","article-title":"Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)","volume":"110","author":"Turner","year":"2014","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s13063-016-1624-6","article-title":"Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial","volume":"17","author":"Walsh","year":"2016","journal-title":"Trials"},{"issue":"17","key":"10.1002\/14651858.CD004720.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1016\/j.ejca.2010.09.016","article-title":"Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies","volume":"46","author":"Lane","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0057|cit57","unstructured":"Cluster randomised trial of PSA testing for Prostate cancer http:\/\/www.isrctn.com\/ISRCTN92187251"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"Journal of the American Medical Association"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/00005650-199807000-00007","article-title":"The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure","volume":"36","author":"Litwin","year":"1998","journal-title":"Medical Care"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1111\/j.1475-6773.2012.01395.x","article-title":"Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors","volume":"47","author":"Jayadevappa","year":"2012","journal-title":"Health Services Research"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ajco.12070","article-title":"Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer","volume":"10","author":"Bedard","year":"2014","journal-title":"Asia Pacific Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Quality of Life Research"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-8-116","article-title":"Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units","volume":"8","author":"Johnston","year":"2010","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1477-7525-11-109","article-title":"Patient-reported outcomes in meta-analyses \u2013 Part 1: assessing risk of bias and combining outcomes","volume":"11","author":"Johnston","year":"2013","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0067|cit67","unstructured":"EndNote Clarivate Analytics 2016"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0068|cit68","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0069|cit69","unstructured":"Covidence Veritas Health Innovation 2026"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0071|cit71","unstructured":"Higgins P Altman D Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0072|cit72","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0073|cit73","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019 Available at https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v6.0"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0074|cit74","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD004720.pub4-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0078|cit78","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"issue":"9360","key":"10.1002\/14651858.CD004720.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","article-title":"Prostate cancer epidemiology","volume":"361","author":"Gr\u00f6nberg","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0080|cit80","first-page":"74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"17","key":"10.1002\/14651858.CD004720.pub4-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening \u2013 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.euo.2024.11.004","article-title":"Reducing overtreatment of prostate cancer patients: revisiting the European Association of Urology pretreatment risk group classification using long-term follow-up data from the European Randomized study of Screening for Prostate Cancer Rotterdam","volume":"8","author":"De Vos","year":"2025","journal-title":"European Urology Oncology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S0302-2838(25)00085-5","article-title":"Prostate cancer mortality in men not attending a population-based screening program: the good, the bad, and the ugly after 20-year follow-up in the European Randomized study of Screening for Prostate Cancer","volume":"87","author":"Leenen","year":"2025","journal-title":"European Urology"},{"issue":"17","key":"10.1002\/14651858.CD004720.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/j.ejca.2010.09.035","article-title":"Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized study of Screening for Prostate Cancer","volume":"46","author":"Laurila","year":"2010","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2006.07.012","article-title":"Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer \u2013 results from a prospective, population-based randomized controlled trial","volume":"51","author":"Aus","year":"2007","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"27-32","DOI":"10.1016\/j.euros.2021.09.014","article-title":"Intervention-related deaths in the European Randomized study of Screening for Prostate Cancer","volume":"34","author":"Godtman","year":"2021","journal-title":"European Urology Open Science"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0087|cit87","first-page":"e785","article-title":"Outcomes after primary treatment for non-metastasized prostate cancer in the European randomized screening trial for prostate cancer (ERSPC)","volume":"11","author":"Hugosson","year":"2012","journal-title":"Urology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004720.pub4-BIB0088|cit88","first-page":"e210-e211","article-title":"Prostate cancer specific mortality in the ERSPC trial: what is the role of screening result and adherence","volume":"206","author":"Wetterauer","year":"2021","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2023.03.031","article-title":"Relationship between baseline prostate-specific antigen on cancer detection and prostate cancer death: long-term follow-up from the European Randomized study of Screening for Prostate Cancer","volume":"84","author":"Remmers","year":"2023","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0090|cit90","first-page":"e669","article-title":"How screening affects erectile function and urinary continence following radical prostatectomy: results from the European Randomized study of Screening for Prostate Cancer (ERSPC)","volume":"1","author":"Carlsson","year":"2010","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2018.10.053","article-title":"Results of prostate cancer screening in a unique cohort at 19 yr of follow-up","volume":"75","author":"Osses","year":"2019","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.eururo.2011.05.013","article-title":"Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European Randomized study of Screening for Prostate Cancer \u2013 Rotterdam after 11 years of follow-up","volume":"60","author":"Zhu","year":"2011","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bju.16394","article-title":"Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer","volume":"134","author":"Pasanen","year":"2024","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/0969141316652174","article-title":"Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial","volume":"24","author":"Hakama","year":"2017","journal-title":"Journal of Medical Screening"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Van der Kwast TH Ciatto S Martikainen PM Hoedemaeker R Laurila M Pihl CG Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer International Journal of Cancer 2006 118 10 2538 42","DOI":"10.1002\/ijc.21667"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1055-9965.EPI-09-0146","article-title":"Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands","volume":"18","author":"Auvinen","year":"2009","journal-title":"Cancer Epidemiology Biomarkers & Prevention"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2015.02.042","article-title":"Metastatic prostate cancer incidence and prostate-specific antigen testing: new insights from the European Randomized Study of Screening for Prostate Cancer","volume":"68","author":"Buzzoni","year":"2015","journal-title":"European Urology"},{"issue":"18","key":"10.1002\/14651858.CD004720.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.ejca.2011.06.055","article-title":"False-positive screening results in the European Randomized study of Screening for Prostate Cancer","volume":"47","author":"Kilpel\u00e4inen","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2009.07.018","article-title":"Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)","volume":"56","author":"Roobol","year":"2009","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.eururo.2012.05.068","article-title":"Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"62","author":"Schr\u00f6der","year":"2012","journal-title":"European Urology"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD004720.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/bjc.2016.378","article-title":"Impact of cause of death adjudication on the results of the European prostate cancer screening trial","volume":"116","author":"Walter","year":"2017","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S1569-9056(12)60782-9","article-title":"Outcomes after various primary treatment for non-metastasised prostate cancer. A report from the European randomized screening trial for prostate cancer (ERSPC)","volume":"11","author":"Carlsson","year":"2012","journal-title":"European Urology Supplements"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0105|cit105","first-page":"S12","article-title":"Outcomes after primary treatment for non-metastasized prostate cancer in the European Randomized Screening trial for Prostate Cancer (ERSPC)","volume":"80","author":"Hugosson","year":"2012","journal-title":"Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0106|cit106","first-page":"10","article-title":"Impact of prostatic-specific antigen threshold and screening interval in prostate cancer screening outcomes: comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres","volume":"10","author":"Saarimaki","year":"2017","journal-title":"European Urology Focus"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1464-410X.2011.10811.x","article-title":"Increased non-prostate cancer death risk in clinically diagnosed prostate cancer","volume":"110","author":"Van Leeuwen","year":"2012","journal-title":"BJU International"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ijc.24870","article-title":"The effect of study arm on prostate cancer treatment in the large screening trial ERSPC","volume":"126","author":"Wolters","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"9959","key":"10.1002\/14651858.CD004720.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0969141313476632","article-title":"Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial","volume":"20","author":"Van Leeuwen","year":"2016","journal-title":"Journal of Medical Screening"},{"issue":"7651","key":"10.1002\/14651858.CD004720.pub4-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0113|cit113","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2026"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0115|cit115","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.juro.2018.01.080","article-title":"Long-term outcome of a single intervention population based prostate cancer screening study","volume":"200","author":"Lundgren","year":"2018","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.juro.2008.11.115","article-title":"15-year followup of a population based prostate cancer screening study","volume":"181","author":"Kjellman","year":"2009","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2007.04.063","article-title":"Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study","volume":"53","author":"Kjellman","year":"2007","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"S2: 17","DOI":"10.1111\/j.1464-410X.2003.04391.x","article-title":"ERSPC: features and preliminary results from the Antwerp study centre","volume":"92","author":"Nelen","year":"2003","journal-title":"BJU International"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djt038","article-title":"Prostate cancer mortality in the Finnish randomized screening trial","volume":"105","author":"Kilpel\u00e4inen","year":"2013","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/ijc.70026","article-title":"Risk factors for low-risk prostate cancer: a retrospective cohort study within the FinRSPC trial","volume":"157","author":"Okwor Uzoamaka","year":"2025","journal-title":"International Journal of Cancer"},{"issue":"7-8","key":"10.1002\/14651858.CD004720.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/sj.bjc.6690194","article-title":"European randomized study of prostate cancer screening: first-year results of the Finnish trial","volume":"79","author":"Auvinen","year":"1999","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/S1569-9056(12)60151-1","article-title":"Screening failures in Finland: improving prostate cancer screening","volume":"11","author":"Kilpel\u00e4inen","year":"2012","journal-title":"European Urology Supplements"},{"issue":"Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0022-5347(09)61813-9","article-title":"The results of the three rounds of Finnish prostate cancer screening trial","volume":"4","author":"Kilpel\u00e4inen","year":"2009","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605512","article-title":"False-positive screening results in the Finnish prostate cancer screening trial","volume":"102","author":"Kilpel\u00e4inen","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0022-5347(05)65764-3","article-title":"Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng. \/ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests","volume":"166","author":"M\u00e4kinen","year":"2001","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0128|cit128","first-page":"17","article-title":"Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer","volume":"17","author":"Lindberg","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ijc.34274","article-title":"Prostate cancer incidence in men with prostate-specific antigen below 3 ng\/mL: the Finnish Randomized Study of Screening for Prostate Cancer","volume":"152","author":"Ola","year":"2023","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0130|cit130","first-page":"15","article-title":"The number of screening cycles needed to reduce prostate cancer mortality in the Finnish section of the European randomized study of prostate cancer (ERSPC)","volume":"15","author":"Pakarainen","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10552-023-01828-2","article-title":"Screening history and risk of death from prostate cancer: a nested case-control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC)","volume":"35(4)","author":"Talala","year":"2024","journal-title":"Cancer Causes & Control"},{"issue":"15","key":"10.1002\/14651858.CD004720.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1002\/cam4.3181","article-title":"Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer","volume":"9","author":"Talala","year":"2020","journal-title":"Cancer Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ijc.20352","article-title":"Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial","volume":"111","author":"Auvinen","year":"2004","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.1996.402","article-title":"Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland","volume":"74","author":"Auvinen","year":"1996","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eururo.2012.11.041","article-title":"Health-related quality of life in the Finnish trial of screening for prostate cancer","volume":"65","author":"Booth","year":"2014","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Finne P Stenman UH M\u00e4\u00e4tt\u00e4nen L M\u00e4kinen T Tammela TL Martikainen P The Finnish trial of prostate cancer screening: where are we now? BJU International 2003 92 Suppl 2 22 6","DOI":"10.1111\/j.1465-5101.2003.04397.x"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ijc.25368","article-title":"Results of the three rounds of the Finnish prostate cancer screening trial--the incidence of advanced cancer is decreased by screening","volume":"127","author":"Kilpel\u00e4inen","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2016.08.022","article-title":"Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"45","author":"Kilpel\u00e4inen","year":"2016","journal-title":"Cancer Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2017.01.048","article-title":"Estimate of opportunistic prostate specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"198","author":"Kilpel\u00e4inen","year":"2017","journal-title":"Journal Urology"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/1078-0432.CCR-03-0338","article-title":"Second round results of the Finnish population-based prostate cancer screening trial","volume":"10","author":"Tammela","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.eururo.2016.05.009","article-title":"Number of screening rounds and postscreening prostate cancer incidence: results from the Finnish section of the European Randomized Study of Screening for Prostate Cancer Study","volume":"70","author":"Pakarainen","year":"2016","journal-title":"European Urology"},{"issue":"8","key":"10.1002\/14651858.CD004720.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3109\/0284186X.2013.802837","article-title":"Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC)","volume":"52","author":"Vasarainen","year":"2013","journal-title":"Acta Oncologica"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1569-9056(09)60293-1","article-title":"The results of the three rounds of Finnish prostate cancer screening trial","volume":"8","author":"Kilpel\u00e4inen","year":"2009","journal-title":"European Urology Supplements"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S1569-9056(15)60027-6","article-title":"Risk of prostate cancer after PSA screening: results from the Finnish section of ERSPC","volume":"14","author":"Pakarainen","year":"2015","journal-title":"European Urology Supplements"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/93.7.552","article-title":"Three-year results of the Finnish prostate cancer screening trial","volume":"93","author":"M\u00e4\u00e4tt\u00e4nen","year":"2001","journal-title":"Journal of the National Cancer Institute"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004720.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000052581","article-title":"Randomized screening trial for prostate cancer in Finland","volume":"39","author":"Hakama","year":"2001","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.purol.2020.02.011","article-title":"Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"30","author":"Villers","year":"2020","journal-title":"Progres en Urologie"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.purol.2009.03.001","article-title":"Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with prostate specific antigen: French departments of Tarn and H\u00e9rault","volume":"19","author":"Jegu","year":"2009","journal-title":"Progres en Urologie"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"S2: 30","DOI":"10.1111\/j.1465-5101.2003.04394.x","article-title":"Specific features of the Italian section of the ERSPC","volume":"92","author":"Ciatto","year":"2003","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2013.05.030","article-title":"Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer","volume":"64","author":"Roobol","year":"2013","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ijc.11074","article-title":"Effective PSA contamination in the Rotterdam section of the European randomized study of screening for prostate cancer","volume":"105","author":"Otto","year":"2003","journal-title":"International Journal of Cancer"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"S1079","DOI":"10.1016\/j.eururo.2025.09.3479","article-title":"Does baseline PSA density predict prostate cancer specific mortality? 21 years follow-up of the ERSPC Rotterdam","volume":"87","author":"Van Harten","year":"2025","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.eururo.2006.07.052","article-title":"Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam","volume":"51","author":"De Vries","year":"2007","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1-6","DOI":"10.1016\/j.euros.2023.02.013","article-title":"The patient journey from randomization to detection of prostate cancer and death: results from ERSPC rotterdam","volume":"51","author":"Remmers","year":"2023","journal-title":"European Urology Open Science"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0155|cit155","first-page":"241","article-title":"European randomized study of screening for prostate cancer (ERSPC, section Rotterdam): overview and characterization of cancers found with low PSA values","volume":"80","author":"Schr\u00f6der","year":"1997","journal-title":"British Journal of Urology"},{"issue":"5-6","key":"10.1002\/14651858.CD004720.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1159\/000019894","article-title":"The European Randomized study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam","volume":"35","author":"Schr\u00f6der","year":"1999","journal-title":"European Urology"},{"issue":"12","key":"10.1002\/14651858.CD004720.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/ijc.25947","article-title":"Identifying and characterizing \"escapes\" \u2013 men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)","volume":"129","author":"Zhu","year":"2011","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer","volume":"84","author":"Meertens","year":"2023","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.euo.2023.08.011","article-title":"From screening to mortality reduction: an overview of empirical data on the patient journey in European randomized study of screening for prostate cancer Rotterdam after 21 years of follow-up and a reflection on quality of life","volume":"7","author":"Hogenhout","year":"2023","journal-title":"European Urology Oncology"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/ijc.25278","article-title":"Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)","volume":"127","author":"Kerkhof","year":"2010","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0161|cit161","unstructured":"European randomized study of screening for prostate cancer Erasmus Medical Center, Department of Urology 2005"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0162|cit162","unstructured":"European randomized study of screening for prostate cancer https:\/\/onderzoekmetmensen.nl\/en\/trial\/29632"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004720.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"S1607","DOI":"10.1016\/S0302-2838(24)01235-1","article-title":"Differences in quality of curative treatment and outcome in men with localised prostate cancer in the screening and control arms of the ERSPC Rotterdamse","volume":"85","author":"De Vos","year":"2024","journal-title":"European Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004720.pub4-BIB0164|cit164","first-page":"S27","article-title":"Risk groups and prostate cancer mortality 12 years after detection: European randomized study of screening for prostate cancer (ERSPC), Rotterdam Center","volume":"82","author":"Roobol","year":"2013","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bju.13913","article-title":"Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer","volume":"120","author":"Chiu","year":"2017","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0166|cit166","first-page":"e801-","article-title":"From screening to mortality reduction: an overview of the patient journey in ERSPC Rotterdam","volume":"203","author":"Roobol","year":"2020","journal-title":"Journal of Urology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0167|cit167","first-page":"e668","article-title":"The effect of non-compliance and PSA testing before study in the intervention arm of the European Randomized Study of screening for Prostate Cancer section Rotterdam","volume":"183","author":"Van Leeuwen","year":"2010","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.eururo.2011.01.001","article-title":"Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng\/ml who are participating in ERSPC Rotterdam","volume":"59","author":"Bul","year":"2011","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0022-5347(18)37885-6","article-title":"Four year prostate specific antigen (PSA) progression and prostate cancer detection in the European randomized study of screening for prostate cancer (ERSPC), section Rotterdam","volume":"171","author":"Raaijmakers","year":"2004","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/jnci\/djm101","article-title":"Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam","volume":"99","author":"Roobol","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01.ju.0000165568.76908.5c","article-title":"4 year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam","volume":"174","author":"Schr\u00f6der","year":"2005","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1569-9056(11)60025-0","article-title":"Disease-specific survival in men with interval cancers compared to men with cancers in the control arm: long-term results of the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"10","author":"Zhu","year":"2011","journal-title":"European Urology Supplements"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S1569-9056(13)60500-X","article-title":"Disease-specific survival of men with screen-detected prostate cancer: comparison of first round vs second round cancers in an European randomized screening trial","volume":"12","author":"Zhu","year":"2013","journal-title":"European Urology Supplements"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0174|cit174","doi-asserted-by":"crossref","unstructured":"Bokhorst LP Kranse R Venderbos LD Salman JW Van Leenders GJ Schr\u00f6der FH Differences in treatment and outcome after treatment with curative intent in the screening and control arms of the ERSPC Rotterdam European Urology 2015 68 2 179 82","DOI":"10.1016\/j.eururo.2014.10.008"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2003.04391.x","article-title":"ERSPC: features and preliminary results from the Antwerp study centre","volume":"92","author":"Nelen","year":"2003","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0176|cit176","doi-asserted-by":"crossref","unstructured":"Postma R Schr\u00f6der FH Van Leenders GJ Hoedemaeker RF Vis AN Roobol MJ Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening European Urology 2007 52 1 89 97","DOI":"10.1016\/j.eururo.2007.01.030"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jnci\/dji121","article-title":"Rotterdam randomized pilot studies of screening for prostate cancer \u2013 an overview after 10 years","volume":"97","author":"Schr\u00f6der","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.eururo.2011.05.013","article-title":"Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer \u2013 Rotterdam after 11 years of follow-up","volume":"60","author":"Zhu","year":"2011","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0094-0143(05)70377-3","article-title":"Prostate-specific antigen as a screening test. The Netherlands experience","volume":"24","author":"Bangma","year":"1997","journal-title":"Urologic Clinics of North America"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1464-410X.2012.11481.x","article-title":"Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial","volume":"110","author":"Bokhorst","year":"2012","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/pcan.2014.7","article-title":"Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening For Prostate Cancer (ERSPC)","volume":"17","author":"Luj\u00e1n","year":"2014","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.acuroe.2015.06.004","article-title":"Update of the results of the Spanish branch of the European Randomized study on Screening for Prostate Cancer (ERSPC)","volume":"39","author":"Luj\u00e1n","year":"2015","journal-title":"Actas Urologicas Espanolas (English Ed)"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1016\/S1569-9056(14)60836-8","article-title":"Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"13","author":"P\u00e1ez","year":"2014","journal-title":"European Urology Supplements"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0184|cit184","first-page":"737","article-title":"Preliminary data of the Spanish contribution to the European Randomized Study on Screening of Prostate Cancer (ERSPC)","volume":"60","author":"Torres","year":"2007","journal-title":"Archivos Espanoles de Urologia"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.acuroe.2016.02.005","article-title":"Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"40","author":"Luj\u00e1n","year":"2016","journal-title":"Actas Urologicas Espanolas (English Ed)"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.acuroe.2011.10.004","article-title":"Mortality due to prostate cancer in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Results after a 15-year follow-up","volume":"36","author":"Lujan","year":"2012","journal-title":"Actas Urologicas Espanolas (English Ed)"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.acuroe.2020.07.001","article-title":"Results of the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up","volume":"44","author":"Galan","year":"2020","journal-title":"Actas Urologicas Espanolas (English Ed)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1465-5101.2003.04393.x","article-title":"The Spanish contribution to the European Randomized study of Screening for Prostate Cancer","volume":"92","author":"Berenguer","year":"2003","journal-title":"BJU International"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the G\u00f6teborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scandinavian Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2025.06.012","article-title":"Active surveillance for screen-detected low- and intermediate-risk prostate cancer: extended follow-up up to 25 years in the GOTEBORG-1 trial","volume":"88","author":"Palmstedt","year":"2025","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0022-5347(18)32055-X","article-title":"Diagnostic accuracy of prostate-specific antigen testing in unscreened men: results from the European randomized study of prostate cancer screening in G\u00f6teborg, Sweden","volume":"177","author":"Lilja","year":"2007","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1569-9056(09)60298-0","article-title":"Results after 7 screening rounds in the G\u00f6thenburg branch of ERSPC","volume":"8","author":"Hugosson","year":"2009","journal-title":"European Urology Supplements"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eururo.2022.10.006","article-title":"Young age on starting prostate-specific antigen testing is associated with a greater reduction in prostate cancer mortality: 24-year follow-up of the Goteborg randomized population-based prostate cancer screening trial","volume":"83(2)","author":"Carlsson","year":"2023","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.ejca.2007.06.002","article-title":"Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - results from a prospective, population-based, randomised study","volume":"43","author":"Carlsson","year":"2007","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/21681805.2018.1508166","article-title":"Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng\/mL: results from the Goteborg randomized population-based prostate cancer screening trial","volume":"52","author":"Franlund","year":"2018","journal-title":"Scandinavian Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of follow-up in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1569-9056(11)60301-1","article-title":"The effect of age and number of screening visits on the cumulative risk of prostate cancer. Results from the G\u00f6thenburg randomised screening trial","volume":"10","author":"Godtman","year":"2011","journal-title":"European Urology Supplements"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of follow-up in the Goteborg randomized population-based prostate cancer screening trial","volume":"208","author":"Franlund","year":"2022","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/JU.0000000000002835","article-title":"Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial","volume":"208","author":"Stinesen Kollberg","year":"2022","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"e1094","DOI":"10.1016\/S1569-9056(12)61090-2","article-title":"Outcome following surveillance of men with screen-detected prostate cancer. Results from the Gothenburg randomised population-based prostate cancer screening trial","volume":"11","author":"Arnsrud Godtman","year":"2012","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0201|cit201","first-page":"302","article-title":"No excess mortality after prostate biopsy: Results from the European randomized study of screening for prostate cancer (ERSPC)","volume":"9","author":"Carlsson","year":"2010","journal-title":"European Urology Supplements"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1569-9056(13)60497-2","article-title":"Incidence and mortality of prostate cancer after termination of PSA based screening","volume":"12","author":"Grenabo","year":"2013","journal-title":"European Urology Supplements"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S1569-9056(16)60089-1","article-title":"18-year follow up of the Gothenburg randomized population-based prostate cancer screening trial","volume":"15","author":"Arnsrud Godtman","year":"2016","journal-title":"European Urology Supplements"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2006.07.012","article-title":"Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer \u2013 results from a prospective, population-based randomized controlled trial","volume":"51","author":"Aus","year":"2007","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejca.2010.10.016","article-title":"The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The G\u00f6teborg randomised population-based prostate cancer screening trial","volume":"47","author":"Carlsson","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0207|cit207","first-page":"e669","article-title":"How screening does affect erectile function and urinary continence following radical prostatectomy \u2013 results from the European Randomized Study of Screening for Prostate Cancer (ERSPC)","volume":"4","author":"Carlsson","year":"2010","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"e850","DOI":"10.1016\/S1569-9056(14)60837-X","article-title":"A comparison of the effectiveness of organised versus opportunistic screening measured as number need to invite (NNI) and number needed to diagnose (NND). Results from the G\u00f6thenburg randomised population-based prostate cancer screening trial","volume":"13","author":"Godtman","year":"2014","journal-title":"European Urology Supplements"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2013.05.024","article-title":"Incidence of prostate cancer after termination of screening in a population-based randomised screening trial","volume":"64","author":"Grenabo Bergdahl","year":"2013","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1569-9056(11)60031-6","article-title":"Results from the G\u00f6thenburg randomised prostate cancer screening trial","volume":"10","author":"Hugosson","year":"2011","journal-title":"European Urology Supplements"},{"issue":"Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0022-5347(09)62224-2","article-title":"Experience from 14 years of biennial PSA-based screening. The G\u00f6teborg branch of ERSPC","volume":"4","author":"Hugosson","year":"2009","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/01.ju.0000061183.43229.2e","article-title":"Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable","volume":"169","author":"Hugosson","year":"2003","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/cncr.20126","article-title":"Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma","volume":"100","author":"Hugosson","year":"2004","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD004720.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"e848","DOI":"10.1016\/S1569-9056(14)60835-6","article-title":"18-year follow-up from the Gothenburg randomised prostate cancer screening trial","volume":"13","author":"Hugosson","year":"2014","journal-title":"European Urology Supplements"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S1569-9056(17)30300-7","article-title":"At what age should a PSA-based screening program start? 20-year results from the Goteborg randomized population-based prostate cancer screening study","volume":"16","author":"Carlsson","year":"2017","journal-title":"European Urology Supplements"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.eururo.2006.07.013","article-title":"Prostate cancer in the Swedish section of ERSPC \u2013 evidence for less metastases at diagnosis but not for mortality reduction","volume":"51","author":"Schr\u00f6der","year":"2007","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0218|cit218","first-page":"302","article-title":"How screening does affect erectile function and urinary continence following radical prostatectomy: Results from the European Randomized study of Screening for Prostate Cancer (ERSPC)","volume":"9","author":"Carlsson","year":"2010","journal-title":"European Urology Supplements"},{"issue":"12","key":"10.1002\/14651858.CD004720.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1111\/j.1464-410X.2010.09712.x","article-title":"No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer","volume":"107","author":"Carlsson","year":"2011","journal-title":"BJU International"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1465-5101.2003.04396.x","article-title":"Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden","volume":"92","author":"Hugosson","year":"2003","journal-title":"BJU International"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1569-9056(09)60294-3","article-title":"Cumulative incidence of prostate cancer in men participating in a repeated PSA based screening study: results from the G\u00f6thenburg branch of ERSPC","volume":"8","author":"Hugosson","year":"2009","journal-title":"European Urology Supplements"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0222|cit222","unstructured":"The G\u00f6teborg randomised population based prostate cancer screening trial http:\/\/www.isrctn.com\/ISRCTN54449243"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S1569-9056(12)60266-8","article-title":"Efficacy vs. effectiveness study design within the European Randomized Study of Screening for Prostate Cancer: consequences for prostate cancer incidence, overall mortality and disease-specific mortality","volume":"11","author":"Zhu","year":"2012","journal-title":"European Urology Supplements"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scandinavian Journal of Urology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0225|cit225","first-page":"e547","article-title":"Screening for prostate cancer: Results from the Swiss section of the ERSPC (AARAU)","volume":"195","author":"Kwiatkowski","year":"2016","journal-title":"Journal of Urology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1465-5101.2003.04395.x","article-title":"Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland","volume":"92","author":"Kwiatkowski","year":"2003","journal-title":"BJU International"},{"issue":"39-40","key":"10.1002\/14651858.CD004720.pub4-BIB0227|cit227","first-page":"580","article-title":"Screening for prostate cancer: results of a prospective trial in Canton Aargau, Switzerland","volume":"134","author":"Kwiatkowski","year":"2004","journal-title":"Swiss Medical Weekly"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0228|cit228","first-page":"e793","article-title":"Prostate specific antigen (PSA)-pyramid in men with low range PSA: prostate cancer incidence and mortality \u2013 a plea for risk-based prostate cancer screening strategy in the European Randomized Study of Screening for Prostate Cancer (ERSPC), AARAU","volume":"189","author":"Randazzo","year":"2013","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S1569-9056(15)60118-X","article-title":"Family history as a risk factor for prostate cancer in a contemporary screening trial \u2013 results of the Swiss ERSPC (Aarau)","volume":"14","author":"Randazzo","year":"2015","journal-title":"European Urology Supplements"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU International"},{"issue":"309","key":"10.1002\/14651858.CD004720.pub4-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2147\/RRU.S542550","article-title":"Ten-year trends in digital rectal exam results and prostate cancer detection: insights from the PLCO trial","volume":"17","author":"Guan","year":"2025","journal-title":"Research and Reports in Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0232|cit232","first-page":"1372","article-title":"Other- and all-cause mortality among men diagnosed with prostate cancer in the PLCO trial","volume":"205","author":"Pierre-Victor","year":"2020","journal-title":"Journal of Urology 2020"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/1574887113666180409153059","article-title":"Overall and multiphasic findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) randomized cancer screening trial","volume":"13","author":"Prorok","year":"2018","journal-title":"Reviews on Recent Clinical Trials"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004720.pub4-BIB0234|cit234","first-page":"15","article-title":"PSA (prostate-specific-antigen) screening to improve outcome in prostate cancer (PC): reanalysis of the Prostate-Lung-Colorectal-Ovary (PLCO) randomized controlled trial (RCT)","volume":"36","author":"Zhang","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0235|cit235","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/pros.23540","article-title":"Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial","volume":"78","author":"Miller","year":"2018","journal-title":"Prostate"},{"issue":"17","key":"10.1002\/14651858.CD004720.pub4-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/cncr.32176","article-title":"Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","volume":"125","author":"Pinsky","year":"2019","journal-title":"Cancer"},{"issue":"13","key":"10.1002\/14651858.CD004720.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Berg","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.canep.2012.08.008","article-title":"Prostate cancer specific survival in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial","volume":"36","author":"Pinsky","year":"2012","journal-title":"Cancer Epidemiology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0239|cit239","doi-asserted-by":"crossref","unstructured":"Prorok PC Andriole GL Bresalier RS Buys SS Chia D Crawford ED Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial Controlled Clinical Trials 2000 21 6 Suppl 273s 309s","DOI":"10.1016\/S0197-2456(00)00098-2"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jnci\/dji065","article-title":"Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial","volume":"97","author":"Andriole","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-3-642-45195-9_6","article-title":"Update of the Prostate, Lung, Colorectal, and Ovarian cancer screening trial","volume":"202","author":"Andriole","year":"2014","journal-title":"Recent Results in Cancer Research"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0242|cit242","doi-asserted-by":"crossref","unstructured":"Crawford ED Grubb R Black A Andriole GL Chen MH Izmirlian G Comorbidity and mortality results from a randomized prostate cancer screening trial Journal of Clinical Oncology 2011 29 4 355 61","DOI":"10.1200\/JCO.2010.30.5979"},{"issue":"18","key":"10.1002\/14651858.CD004720.pub4-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA testing rates in the PLCO trial","volume":"374","author":"Shoag","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"10.1002\/14651858.CD004720.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0022-5347(09)61815-2","article-title":"Initial PSA levels and prostate cancer diagnosis with up to 7 years follow-up in the PLCO cancer screening trial","volume":"181","author":"Black","year":"2009","journal-title":"Journal of Urology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/jco.2013.31.15_suppl.5022","article-title":"Mortality at 120 days following prostatic biopsy: analysis of data in the PLCO study","volume":"31","author":"Boniol","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0022-5347(09)62145-5","article-title":"Potential for increase in screening interval based on initial PSA: data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial","volume":"181","author":"Crawford","year":"2009","journal-title":"Journal of Urology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD004720.pub4-BIB0248|cit248","first-page":"e224","article-title":"Factors influencing prostate cancer mortality in the PLCO Trial","volume":"183","author":"Crawford","year":"2010","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.juro.2016.08.092","article-title":"Prognostic significance of digital rectal examination and prostate specific antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening arm","volume":"197","author":"Halpern","year":"2017","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD004720.pub4-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamaoncol.2015.2993","article-title":"Efficacy of prostate-specific antigen screening: use of regression discontinuity in the PLCO cancer screening trial","volume":"1","author":"Shoag","year":"2015","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"Pinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0252|cit252","unstructured":"Screening for prostate cancer in older patients (PLCO screening trial) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00002540"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1370\/afm.942","article-title":"Cumulative incidence of false-positive results in repeated, multimodal cancer screening","volume":"7","author":"Croswell","year":"2009","journal-title":"Annals of Family Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1464-410X.2008.08214.x","article-title":"Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial","volume":"102","author":"Pinsky","year":"2008","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bju.12368","article-title":"Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial","volume":"113","author":"Pinsky","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0256|cit256","doi-asserted-by":"crossref","unstructured":"Shoag J Mittal S Halpern JA Scherr D Hu JC Barbieri CE Lethal prostate cancer in the PLCO cancer screening trial European Urology 2016 70 1 2 5","DOI":"10.1016\/j.eururo.2016.01.009"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0090-4295(96)00061-1","article-title":"Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program","volume":"47","author":"Crawford","year":"1996","journal-title":"Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0969141319839097","article-title":"Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","volume":"26","author":"Pinsky","year":"2019","journal-title":"Journal of Medical Screening"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/pros.20017","article-title":"Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial","volume":"59","author":"Labrie","year":"2004","journal-title":"Prostate"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B","article-title":"Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial","volume":"38","author":"Labrie","year":"1999","journal-title":"Prostate"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/13685539909003181","article-title":"Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening","volume":"2","author":"Labrie","year":"1999","journal-title":"Aging Male"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2018.10.053","article-title":"Results of prostate cancer screening in a unique cohort at 19 yr of follow-up","volume":"75","author":"Osses","year":"2019","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1464-410X.2003.04390.x","article-title":"Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)","volume":"92 Suppl 2","author":"Roobol","year":"2003","journal-title":"BJU International"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD004720.pub4-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S1569-9056(18)31111-4","article-title":"Screening and prostate cancer mortality: Results of a unique cohort at 19 years of followup","volume":"17","author":"Osses","year":"2018","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2003.04391.x","article-title":"ERSPC: features and preliminary results from the Antwerp study centre","volume":"92 Suppl 2","author":"Nelen","year":"2003","journal-title":"BJU International"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/jnci\/dji121","article-title":"Rotterdam randomized pilot studies of screening for prostate cancer - An overview after 10 years","volume":"97","author":"Schroder","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-0215(19960117)65:2<145::AID-IJC4>3.0.CO;2-Z","article-title":"European randomized study of screening for prostate cancer--the Rotterdam pilot studies","volume":"65","author":"Shr\u00f6der","year":"1996","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/1097-0142(19950701)76:1<129::AID-CNCR2820760120>3.0.CO;2-1","article-title":"European randomized study of screening for prostate cancer. progress report of Antwerp and Rotterdam pilot studies","volume":"76","author":"Schr\u00f6der","year":"1995","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004720.pub4-BIB0270|cit270","doi-asserted-by":"publisher","first-page":"S1089","DOI":"10.1016\/j.eururo.2025.09.3487","article-title":"Changes in PSA and 4Kscore from the first to the second round of ProScreen screening trial","volume":"87","author":"Auvinen","year":"2025","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0271|cit271","unstructured":"A randomized trial of early detection of clinically significant prostate cancer (ProScreen) https:\/\/clinicaltrials.gov\/study\/NCT03423303"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0272|cit272","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0302-2838(25)00085-5","article-title":"Auvinen AP, Tammela TL, Mirtti T, Lilja H, Tolonen T, Kentt\u00e4mies A, et al","volume":"87","author":"How to improve prostate cancer screening?","year":"2025","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0273|cit273","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0302-2838(25)00085-5","article-title":"MRI findings in men who were screening positive in the first and the second screening round of the randomized ProScreen prostate cancer screening trial","volume":"87","author":"Rannikko","year":"2025","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40644-020-00351-w","article-title":"Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study","volume":"20","author":"Hietikko","year":"2020","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0275|cit275","doi-asserted-by":"publisher","first-page":"e075595","DOI":"10.1136\/bmjopen-2023-075595","article-title":"Early detection of clinically significant prostate cancer: protocol summary and statistical analysis plan for the ProScreen randomised trial","volume":"14","author":"Nevalainen","year":"2024","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0276|cit276","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10654-017-0292-5","article-title":"A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale","volume":"32","author":"Auvinen","year":"2017","journal-title":"European Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0277|cit277","doi-asserted-by":"publisher","first-page":"e1535","DOI":"10.1016\/S1569-9056(19)31106-6","article-title":"A population-based randomized trial of early detection of clinically significant prostate cancer (ProScreen): pilot phase results","volume":"18","author":"Rannikko","year":"2019","journal-title":"European Urology Supplements"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004720.pub4-BIB0278|cit278","first-page":"S5","article-title":"P5 First screening round results of the ProScreen trial with PSA, kallikrein panel and MRI","volume":"63","author":"Tammela","year":"2024","journal-title":"European Urology Open Science"},{"issue":"23","key":"10.1002\/14651858.CD004720.pub4-BIB0279|cit279","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0280|cit280","doi-asserted-by":"publisher","first-page":"S1074","DOI":"10.1016\/j.eururo.2025.09.3474","article-title":"Reults after repeated screening for prostate cancer with PSA and MRI","volume":"87","author":"Hugosson","year":"2025","journal-title":"European Urology"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD004720.pub4-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"S1087","DOI":"10.1016\/j.eururo.2025.09.3485","article-title":"PSA adjusted intervals in prostate cancer screening","volume":"87","author":"Hugosson","year":"2025","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0282|cit282","first-page":"S912-S913","article-title":"Complications after transrectal ultrasound guided biopsies in screening for prostate cancer with PSA followed by MRI - results from the G\u00f6teborg prostate cancer screening 2 trial","volume":"81","author":"Kohestani","year":"2022","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2024.01.017","article-title":"Prostate cancers in the prostate-specific antigen interval of 1.8-3 ng\/ml: results from the goteborg-2 prostate cancer screening trial","volume":"86","author":"Moller","year":"2024","journal-title":"European Urology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD004720.pub4-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"S1269","DOI":"10.1016\/S0302-2838(23)00932-6","article-title":"Prostate cancers detected in the PSA interval 1.8-3 ng\/mL - results from the Goteborg 2 prostate cancer screening trial","volume":"83","author":"Moller Billig","year":"2023","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0285|cit285","unstructured":"The G\u00f6teborg prostate cancer screening 2 trial http:\/\/www.isrctn.com\/ISRCTN94604465"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0286|cit286","unstructured":"China Randomized Study of Screening for Prostate Cancer https:\/\/www.chictr.org.cn\/showproj.html?proj=255823"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"d1539","DOI":"10.1136\/bmj.d1539","article-title":"Randomised prostate cancer screening trial: 20 year follow-up","volume":"342","author":"Sandblom","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0288|cit288","unstructured":"Norrk\u00f6ping randomised controlled trial of prostate cancer screening http:\/\/www.isrctn.com\/ISRCTN06342431"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8510(98)00037-2","article-title":"Economic evaluation of screening for prostate cancer: A randomized population based programme during a 10-year period in Sweden","volume":"45","author":"Holmberg","year":"1998","journal-title":"Health Policy"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0168-8510(90)90425-D","article-title":"Costs and benefits of early detection of prostatic cancer","volume":"16","author":"Carlsson","year":"1990","journal-title":"Health Policy"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2004.08.011","article-title":"Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden","volume":"46","author":"Sandblom","year":"2004","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/00365590410028890","article-title":"Costs and effects of prostate cancer screening in Sweden: A 15-year follow-up of a randomized trial","volume":"38","author":"Sennfalt","year":"2004","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004720.pub4-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3109\/02841869209089713","article-title":"Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population","volume":"31","author":"Varenhorst","year":"1992","journal-title":"Acta Oncologica"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1470-2045(08)70104-9","article-title":"Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study","volume":"9","author":"Collin","year":"2008","journal-title":"Lancet Oncology"},{"issue":"10071","key":"10.1002\/14651858.CD004720.pub4-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncology"},{"issue":"13","key":"10.1002\/14651858.CD004720.pub4-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/cncr.27941","article-title":"Agent Orange as a risk factor for high-grade prostate cancer","volume":"119","author":"Ansbaugh","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0298|cit298","first-page":"290","article-title":"Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"145","DOI":"10.7326\/0003-4819-158-3-201302050-00003","article-title":"Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms","volume":"158","author":"Gulati","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004720.pub4-BIB0300|cit300","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/bmjebm-2023-112238","article-title":"Deceptive shifts in cancer stage distribution","volume":"29","author":"Oke","year":"2023","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0304|cit304","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720.pub2","article-title":"Screening for prostate cancer","author":"Ilic","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0305|cit305","unstructured":"Prostate cancer screening with a PSA test: IQWiG Reports \u2013 Commission No. S19-01 https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558459\/"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0306|cit306","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0307|cit307","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0308|cit308","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"Journal of Clinical Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD004720.pub4-BIB0309|cit309","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.7326\/annals-25-00548","article-title":"GRADE certainty ratings: thresholds rather than categories of contextualization (GRADE guidance 41)","volume":"178","author":"Hultcrantz","year":"2025","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0310|cit310","doi-asserted-by":"publisher","first-page":"111639","DOI":"10.1016\/j.jclinepi.2024.111639","article-title":"Defining decision thresholds for judgments on health benefits and harms using the grading of recommendations assessment, development, and evaluation (GRADE) evidence to decision (EtD) frameworks: a randomized methodological study (GRADE-THRESHOLD)","volume":"179","author":"Morgano","year":"2025","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"k3581","DOI":"10.1136\/bmj.k3581","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline","volume":"362","author":"Tikkinen","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncology"},{"issue":"25","key":"10.1002\/14651858.CD004720.pub4-BIB0313|cit313","doi-asserted-by":"publisher","first-page":"00158","DOI":"10.1016\/j.euo.2025.05.015","article-title":"Prostate cancer testing between screening rounds: evidence from the STHLM3-MRI trial","volume":"S2588-9311","author":"Skalt","year":"2025","journal-title":"European Urology Oncology"},{"issue":"16","key":"10.1002\/14651858.CD004720.pub4-BIB0314|cit314","doi-asserted-by":"publisher","first-page":"1667\u201376","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gronberg","year":"2015","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1569-9056(15)60026-4","article-title":"The German risk-adapted PCA screening trial (PROBASE)-first results","volume":"14","author":"Arsov","year":"2015","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.34295","article-title":"Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial","volume":"152","author":"Krilaviciute","year":"2023","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2013.05.022","article-title":"Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial","volume":"64","author":"Arsov","year":"2013","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2013.05.022","article-title":"Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial","volume":"64","author":"Semjonow","year":"2013","journal-title":"European Urology"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0319|cit319","doi-asserted-by":"publisher","first-page":"1861\u20139","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men \u2013 results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"e0153417","DOI":"10.1371\/journal.pone.0153417","article-title":"Screening coverage needed to reduce mortality from prostate cancer: a living systematic review","volume":"11","author":"Rahal","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"319","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0322|cit322","unstructured":"National Institute for Health and Care Excellence (NICE) Screening for prostate cancer: external review against programme appraisal criteria for the UK National Screening Committee; November 2020 https:\/\/view-health-screening-recommendations.service.gov.uk\/prostate-cancer\/"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0323|cit323","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s1470-2045(21)00348-x","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncology"},{"issue":"18","key":"10.1002\/14651858.CD004720.pub4-BIB0324|cit324","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD004720.pub4-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/bju.15153","article-title":"Prostate cancer screening and treatment: where have we come from and where are we going?","volume":"126","author":"Albertsen","year":"2020","journal-title":"BJU International"},{"issue":"11","key":"10.1002\/14651858.CD004720.pub4-BIB0326|cit326","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1001\/jamainternmed.2014.3078","article-title":"It is time to stop screening for prostate cancer","volume":"174","author":"Prasad","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"23","key":"10.1002\/14651858.CD004720.pub4-BIB0327|cit327","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1002\/cncr.27594","article-title":"The prostate cancer conundrum revisited","volume":"118","author":"Etzioni","year":"2012","journal-title":"Cancer"},{"issue":"13","key":"10.1002\/14651858.CD004720.pub4-BIB0328|cit328","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/nejmsb1616281","article-title":"Prostate cancer screening \u2013 a perspective on the current state of the evidence","volume":"376","author":"Pinsky","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004720.pub4-BIB0329|cit329","doi-asserted-by":"publisher","first-page":"JC94","DOI":"10.7326\/annals-24-01275-jc","article-title":"Prostate cancer screening with MRI does not differ from PSA only for detection but reduces biopsies and overdiagnosis","volume":"177","author":"Wilt","year":"2024","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004720.pub4-BIB0330|cit330","doi-asserted-by":"publisher","first-page":"e231439","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0331|cit331","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1001\/jamaoncol.2016.3600","article-title":"Uptake of active surveillance for very-low-risk prostate cancer in Sweden","volume":"3","author":"Loeb","year":"2017","journal-title":"JAMA Oncology"},{"issue":"15","key":"10.1002\/14651858.CD004720.pub4-BIB0332|cit332","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3238\/arztebl.m2025.0081","article-title":"The probability of remaining under active surveillance for localized prostate cancer: an analysis of young patients in the framework of the multicenter ProjuMa registry study","volume":"122","author":"Claassen","year":"2025","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0333|cit333","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.euo.2024.07.009","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted prostate biopsy: a systematic review and meta-analysis of prospective studies","volume":"7","author":"Zattoni","year":"2024","journal-title":"European Urology Oncology"},{"issue":"10","key":"10.1002\/14651858.CD004720.pub4-BIB0334|cit334","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015990","article-title":"Antibiotic prophylaxis for transperineal prostate biopsy","author":"Xiao","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD004720.pub4-BIB0335|cit335","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004720.pub3","article-title":"Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer","author":"Ilic","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD004720.pub4-BIB0336|cit336","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eururo.2009.01.036","article-title":"Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies","volume":"55","author":"Ficarra","year":"2009","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0337|cit337","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0338|cit338","unstructured":"S3 Guideline: Prostate cancer\u2014Long version 8.1 Available at: https:\/\/hub.leitlinienprogramm-onkologie.de\/leitlinie\/prostatakarzinom"},{"issue":"8","key":"10.1002\/14651858.CD004720.pub4-BIB0339|cit339","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1001\/jamainternmed.2019.0763","article-title":"Decision aids for prostate cancer screening choice: a systematic review and meta-analysis","volume":"179","author":"Riikonen","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004720.pub4-BIB0340|cit340","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001431.pub6","article-title":"Decision aids for people facing health treatment or screening decisions","author":"Stacey","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD004720.pub4-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"g7624","DOI":"10.1136\/bmj.g7624","article-title":"Decision aids that really promote shared decision making: the pace quickens","volume":"350","author":"Agoritsas","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD004720.pub4-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the Prostate cancer Intervention Versus Observation Trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"European Urology"},{"issue":"17","key":"10.1002\/14651858.CD004720.pub4-BIB0343|cit343","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/nejmoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:56Z","timestamp":1792461056000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004720.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":343,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004720.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}